

The involvement of oxidative stress in non-Hodgkin's lymphomas; a review of the literature

Ramona Ingrid Corbeanu

University of Medicine and Pharmacy of Craiova, Department of Pathophysiology, Craiova, Romania

Amelia Maria Găman

University of Medicine and Pharmacy of Craiova, Department of Pathophysiology, Craiova, Romania,
gamanamelia@yahoo.com

Follow this and additional works at: <https://scholar.valpo.edu/jmms>



Part of the [Endocrinology, Diabetes, and Metabolism Commons](#), [Hematology Commons](#), [Internal Medicine Commons](#), and the [Oncology Commons](#)

Recommended Citation

Corbeanu, Ramona Ingrid and Găman, Amelia Maria () "The involvement of oxidative stress in non-Hodgkin's lymphomas; a review of the literature," *Journal of Mind and Medical Sciences*: Vol. 9: Iss. 1, Article 2.

DOI: 10.22543/7674.91.P115

Available at: <https://scholar.valpo.edu/jmms/vol9/iss1/2>

This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in *Journal of Mind and Medical Sciences* by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.

The involvement of oxidative stress in non-Hodgkin's lymphomas; a review of the literature

Ramona Ingrid Corbeanu^{1,2}, Amelia Maria Găman^{2,3*}

¹UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA, DOCTORAL SCHOOL, CRAIOVA, ROMANIA

²UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA, DEPARTMENT OF PATHOPHYSIOLOGY, CRAIOVA, ROMANIA

³FILANTROPIA HOSPITAL OF CRAIOVA, DEPARTMENT OF HEMATOLOGY, CRAIOVA, ROMANIA

ABSTRACT



Non-Hodgkin's malignant lymphomas are a heterogeneous group of hematological malignancies, characterized by a variety of clinical, morphological, histopathological, immuno-histochemical, molecular and evolutionary features. They represent a form of cancer that develops from the lymphatic tissue, as a result of the malignant transformation of B (85%) or T (15%) lymphocytes. Lymphomagenesis is described as a multi-stage process involving the mutation and proliferation of cell clones. Oxidative stress is defined as an imbalance of cellular redox status caused by the production of reactive oxygen species (ROS) and/ or by decreasing antioxidant systems that allows their accumulation in the cell. Small quantities of ROS are involved in physiological mechanisms such as cell growth and differentiation, cell signaling, antimicrobial defense, phagocytosis. Normally, cells are capable of defending themselves against ROS damage through various scavenger systems. On the other hand, excessive ROS contribute to various diseases such as carcinogenesis, ischemia, atherosclerosis, neurodegenerative diseases. Oxidative stress exerts noxious effects on the cell structures by inducing structural changes in membranes, lipids, proteins or DNA. The present review summarizes the latest findings in understanding the ROS-linked signaling pathways in the initiation of lymphomagenesis, disease progression, metastasis, as well as in the pharmacodynamics of specific treatments for this malignancy.

Category: Review

Received: September 25, 2021

Accepted: November 29, 2021

Published: April 10, 2022

Keywords:

reactive oxygen species, oxidative stress, antioxidants, DNA damage, lymphomagenesis, non-Hodgkin's lymphoma

***Corresponding author:**

Amelia Maria Găman,

Craiova University of Medicine and Pharmacy, Department of Pathophysiology, Craiova, Romania, 200349

E-mail: gamanamelia@yahoo.com

Introduction

Non-Hodgkin's lymphoma (NHL) is the most frequent hematological malignancy [1]. The American Cancer Society has estimated 74,200 new cases of NHL for 2019 [2]. The incidence has doubled in the last 50 years, resulting from improved diagnostic techniques and access to medical care. Various classification systems have been developed, but three of them are most commonly used: the National Cancer Institute's Working Formulation (IWF), the Revised European-American Classification of Lymphoid Neoplasms (REAL) and the World Health Organization (WHO) classification [3-5]. The WHO modification of the REAL classification of NHL is based on cell lineage and morphology. In 2016, the World Health Organization's classification of lymphoid, histiocytic and dendritic neoplasms comprises B-line, T-line or Natural Killer (NK) malignancies, post-transplant

lymphoproliferations and histiocytic and dendritic neoplasms, with two sub-divisions: precursor neoplasms and mature differentiated neoplasms [5]. Diagnostic and treatment methods have improved with this revised classification, bringing in the forefront the current cytogenetic and molecular biology data necessary for the most targeted therapeutic management. The natural history of these tumors shows considerable variation. From a clinical-evolutionary point of view, NHL are sorted into three classes: indolent (diffuse lymphocytic B-cell lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, grade I and II follicular lymphoma, Mycosis fungoid), aggressive (B-cell lymphomas: mantle cell lymphoma, grade III follicular lymphoma, large diffuse B-cell lymphoma, primitive mediastinal lymphoma and T-cell lymphomas: angioimmunoblastic, angiocentric, peripheral T-cell, intestinal T-cell, anaplastic with large cells) and very aggressive (lymphoma with B/T precursors,

Burkitt lymphoma and other peripheral T-cell lymphomas). In their evolution, indolent lymphomas can progress to aggressive lymphomas. However, there is a paradox, as aggressive lymphomas have a better prognosis than indolent lymphomas [6,7].

Prognosis mainly depends on individual factors (such as age, comorbidities), lymphoma subtype and extent of lymph node involvement. For a better prediction of the outcome and management, the International Prognostic Index (IPI) and its variant were developed [8,9]. In addition to these factors, recent studies emphasize the importance

of cytogenetic markers in the prognosis, as well as in the therapeutic strategies of NHL [10].

Discussion

Lymphomagenesis is a complex process resulting from the interactions between genetic and environmental factors. It involves a complex, multi-step process, characterized by a progressive clonal expansion of B-cells or T-cells and/or NK-cells. In the first stage, the proliferation is polyclonal under the action of certain risk factors (Table 1).

Table 1. Risk factors for NHL

➤ **Viral infections**

- Epstein-Barr virus is related with the endemic variant of BL [11];
- HTLV-1 causes adult T-cell lymphomas [12];
- Human Herpes virus-8 is associated with Kaposi sarcoma [13];
- Hepatitis B and C - DLBCL and splenic marginal zone lymphoma are the most frequent subtypes due to the infection with the hepatitis C virus [14];

➤ **Bacterial infections**

- *Helicobacter pylori* (HP) untreated and persistent infection has an increased risk of developing a primary gastrointestinal lymphoma [15];
- *Chlamydia psittaci* is responsible for ocular adnexal MALT lymphomas [16];
- *Borrelia burgdorferi* was reported in marginal lymphomas of the skin [17];
- *Campylobacter jejuni* in intestinal lymphomas [18];

➤ **Congenital immunodeficiency conditions**

- Ataxia-telangiectasia;
- Wiskott-Aldrich syndrome;
- Severe combined immunodeficiency disease;

➤ **Acquired immunodeficiency conditions**

- Chronic immunosuppressive treatment (cytostatic drugs, radiotherapy);
- Patients with Human Immunodeficiency Virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) can develop primary central nervous system lymphomas [19];

➤ **Autoimmune diseases**

- Rheumatoid arthritis;
- Sjogren's syndrome;
- Systemic lupus erythematosus;
- Hashimoto's thyroiditis is associated with primary thyroid lymphomas [20];

➤ **Occupational factors:** benzene, dyes, herbicides, pesticides [21-24];

➤ **Family history** of malignant hematological diseases and nutritional factors [25].

Later on, the mutant clone appears as a result of the lesions that affect proto-oncogenes or tumor suppressor genes. The activation of certain oncogenes offers the advantage of autonomous growth and expansion. These oncogenes can be activated by chromosomal translocations or suppressor tumor loci can be inactivated by chromosomal deletions or mutations. Specific

chromosomal alterations are associated with significant changes in gene expression. Translocation (14;18)(q32;q21) produces the overexpression of BCL-2 protein which promotes lymphocyte expansion by inhibiting apoptosis. It is associated with follicular lymphoma (FL), but it has also been described in 30-40% cases of diffuse large B-cell lymphoma germinal center B-cell (GCB-DLBCL) [26,27].

The t(8;14)(q24;q32) involving the MYC oncogene which promotes cell proliferation and development is the most common chromosomal abnormality in Burkitt lymphoma (BL) [28]. The t(2;5)(p23;q35) affects the nucleophosmin (NPM) gene and the anaplastic cell lymphoma kinase (ALK) gene which are described in large cell anaplastic lymphomas occurring in 10-20% cases of pediatric lymphomas and in young adults under 30 years of age [29]. The t(11;14)(q13;q32) is present in most cases of mantle cell lymphoma (MCL) with mutant implications in the BCL-1 gene, leading to rapid cell proliferation [30]. Other mechanisms that involve the inactivation of tumor suppressor genes are linked to lymphomagenesis. It is well-known that the tumor protein p53 encoded by the TP53 gene represents a vital tumor suppressor. This activity is fulfilled through DNA repair, apoptosis, senescence, autophagy via transcription-dependent activity (TA) and transcription-independent activity (TIA) in the nucleus and cytoplasm [31]. Normal functions of these pathways are crucial for tumor suppression. Altered lymphocytes undergo p53-dependent apoptosis. Genomic instability caused by the dysfunction of this gene, along with other chromosomal alterations, allows B lymphocytes to escape immune surveillance, having a polyclonal evolution. Therefore, studies have demonstrated that TP53 mutations initiate and maintain the progression of lymphoproliferative disorders [32]. Moreover, TP53 mutations represent an independent prognostic marker of poor survival in DLBCL patients [33].

The purpose of the latest research includes a better understanding of the signaling pathways involved in lymphomagenesis. In the medical practice, most NHLs are of B-line. Proteins that play a key role in these signaling pathways are affected by the chromosomal changes. Recently, two types of aberrant Signal Transducer and Activator of Transcription (STAT) 3 and 5 have been described, as important effectors of cellular transformation and their connection with hematopoietic cancers [34]. Among NHLs, DLBCL is associated with high-level STAT3 expression and activation, especially the activated B-cell like (ABC-DLBCL). Studies have indicated that different subtypes of peripheral T cell lymphomas (PTCL) and NK lymphomas are linked by activating the mutations of STAT 3 and STAT 5B and increased phosphorylated STAT3 and STAT5B proteins which give growth advantage to transduced cell lines or normal NK cells [35]. STAT 5BN642H mutations has been reported in adult T cell-leukemia/lymphoma and $\gamma\delta$ -T cell lymphomas, like hepato-splenic TCL, primary cutaneous TCL, monomorphic epitheliotropic intestinal TCL, while STAT 3 domain Y640 F and D661Y/V/H/N mutations have been found in T-large granular lymphocyte leukemia, NK, NK/T and adult T cell leukemia/ lymphoma [36].

What is known about the B cell receptor (BCR) signaling pathways in normal B-lymphocytes?

BCR is a signaling complex expressed by the most normal and malignant B lymphocytes. It is a transmembrane signaling complex involved in the proliferation, differentiation, adhesion or apoptosis of these cells [37,38]. Initially, it was considered that an inducible loss of murine BCR causes the death of peripheral B-cells. Subsequently, it was concluded that both ligand-independent activation in the absence of the receptor and the activation sustained by its presence are important in normal B-cell survival. It is thought that the chronic activation of the BCR pathways is responsible for various B-cell malignancies. Studies on B-line lymphomas, such as DLBCL, FL, MCL, and BL have shown major importance in the survival and proliferation of lymphocytes through BCR [39]. Receptor activation is dependent on nuclear factor Kappa-B (NF-kB) and PI3K mediated signaling pathways. Normally, NF-kB is involved in several stages of growth and differentiation of B and T lymphocytes, having a protective role on lymphocyte precursors, ensuring an anti-apoptotic role against tumor necrotic factors (TNF- α) [40]. Constitutional mutations of BCR at immunoglobulins α and β levels have been identified in primary DLBCL, especially in ABC-DLBCL expressing high levels of NF-kB activity and associated with a poor outcome [41]. These mutations are not the only ones which increase the cellular response to BCR activation. Studies demonstrate the existence of additional mutations, such as CARD11 mutation which ensures the activation and potentiates NF-kB activity [42,43].

Many studies have evaluated the role of Wnt signaling pathways in carcinogenesis [44,45]. Normally, this signaling pathway is involved in cell proliferation, differentiation, survival and apoptosis, as well as, angiogenesis. The Wnt signaling pathway is characterized as canonical and non-canonical, B-catenin-dependent and B-catenin-independent. In the absence of the ligand, B-catenin is destroyed by a complex. It binds to receptor-transmembrane frizzled proteins (Fz proteins) and low-density lipoprotein receptor-related protein 5/6 (LRP 5/6) and reaches the nucleus. Through T-cell factor and lymphoid-enhancing factor (Tcf/Lef), transcription factors produce cellular changes. Several studies have documented its involvement in carcinogenesis, leukemogenesis, as well as in lymphomagenesis (DLBCL, BL, and MCL) [46-48].

For a better understanding of the molecular mechanisms underlying the pathogenesis of lymphomas, the researchers studied how signaling pathways potentiate one other. MiR-101 is associated with proliferation, migration, invasion and cell apoptosis [49,50]. Its role in carcinogenesis was demonstrated by various studies [51,52]. Recently, Huang et al. developed a theory

according to which miR-101 expression is down-regulated in DLBCL [53]. Therefore, low levels of miR-101 in patients with DLBCL are correlated with tumor progression by targeting KDM1a pathway.

The involvement of oxidative stress in NHL

Involvement of oxidative stress in lymphomagenesis has been the main aim of several studies [54-57]. Oxygen participates in energy production, a process that takes place in the mitochondria. Following this process, intermediate forms of reactive oxygen (ROS) and nitrogen species (RNS) appear into the body within the basal cell metabolism, but also as a result of the exposure to exogenous factors such as pollution, cigarette smoke or hyperoxia [58]. Numerous enzymes participate in the process of producing free radicals (FR), including nicotinamide-adenine-dinucleotide phosphate (NADPH), succinate dehydrogenase (SDH), cytochrome c reductase, cytochrome b5, monoamine oxidases (MAO-A and MAO-B), pyruvate dehydrogenase complex (PGDH). A variable number of endogenous antioxidant defense systems have the ability of neutralizing ROS. These antioxidant systems include enzymes and non-enzymatic systems [59-61]. Oxidative stress is a biochemical imbalance of cellular redox status caused by the production of reactive oxygen species and/or by decreasing the antioxidant systems that allow their accumulation in the cell [62]. Small quantities of ROS intervene in the physiological mechanisms, such as cell growth and differentiation, cell signaling, antimicrobial defense, phagocytosis. In exchange, large quantities produce pathological processes such as inflammation, carcinogenesis, ischemia, atherosclerosis, neurodegenerative diseases and allergies [63-66].

It is considered that inflammation is a protective mechanism of the body against cell destruction, but there is a correlation between NHL, inflammation and oxidative stress. Sustained antigenic stimulation promotes the clonal proliferation of lymphocytes by inhibiting apoptosis and the activation of NF- κ B by pro-inflammatory cytokines and growth factors [67]. Clonal proliferation is also supported by elevated levels of B lymphocyte growth factor (BAFF/BlyS) as shown in some autoimmune disorders, but also in FL [68]. Oxidative stress can activate a variety of transcription factors that lead to the expression of the genes involved in chronic inflammation, increase the level of pro-inflammatory cytokines (mainly interleukin-1), stimulate and activate B lymphocytes to produce antibodies and alter cellular DNA [69]. Recent studies have shown that genetic variations of pro-inflammatory cytokines (TNF- α , interleukin-10) double the risk of DLBCL, a subtype particularly associated with autoimmune diseases, as demonstrated by other studies [70]. Genomic instability in B lymphocytes, as well as the activation of a transcription factor, NF- κ B, give an advantage of autonomous growth and expansion to mutant

lymphocytes [71]. Therefore, chronic infection disrupts cell growth and survival [72].

Genes controlling the redox homeostasis are important 'actors' in lymphomagenesis, therefore in a multi-center study, performed on 1,172 cases of NHL, ten oxidative stress genes (AKR1A1, AKR1C1, GPX, MPO, NOS2A, NOS3, OGG1, PPARG, SOD2, CYBA) were analyzed and it was established that the genetic variations of these genes lead to a high status of ROS, thus increasing the risk of NHL, especially DLBCL, one of the most common and aggressive subtypes of NHL [73]. Based on this idea, subsequent studies conducted on the Korean population group highlighted the link between the gene polymorphism involved in the DNA repair and the risk of NHL, as follows: four gene genotypes (XRCC1 399 GA, OGG1 326 GG, BRCA1 871 TT and WRN 787 TT) have a low risk of NHL, while MGMT 115 CT genotype is associated with an increased risk. Regarding the MDR1 gene (multidrug resistance 1), genotype 1236 CC is associated with a low risk, while genotypes 3435 CT and TT have an increased risk of NHL [74].

Oxidative stress defined as an imbalance between oxidants and antioxidants, in favor of the oxidants, destroys nuclear and mitochondrial DNA [75] and favors the appearance of specific markers such as 8-hydroxy-2-deoxyguanosine (8-OHdG) [76], protein carbonyl groups as a marker of protein oxidation [77], malondialdehyde (MDA) and F2-isoprostanes as markers of lipid peroxidation [78,79]. Mezayen et al. evaluated the activity of oxidant/antioxidant status in patients with NHL, before and one month after the specific cytotoxic regimen and concluded that there was an increase in MDA and a reduction in SOD levels, thus suggesting that chemotherapy destroys the balance [80]. High-levels of 8-OHdG in tumors, blood samples and urine represent a promising marker for predicting the prognosis of cancers [81-84]. Similarly, other scientists have shown a correlation between elevated 8-OHdG levels and an increased risk of developing malignant hematological diseases [85] and highlighted that elevated urinary levels of 8-OHdG are associated with a poor prognosis in patients with FL [86]. Guanosine hydroxylation is the result of normal metabolism processes and environmental factors, such as exposure to cigarette smoke, asbestos, heavy metals or polycyclic aromatic hydrocarbons. For this purpose, a study conducted by Fenga et al. in 2017 demonstrated that 8-OHdG can be used as a non-invasive marker of early genotoxic DNA damage following the exposure to low doses of benzene [87]. The conclusion was that benzene metabolism (through cytochrome P450) induces FR that affect the oxidant/antioxidant balance, increases the level of ROS and produces increased toxicity, affecting cell proliferation, differentiation and apoptosis (through p38-MAPK signaling pathways, SAPK/JNK, STAT3).

Oxidative stress is involved in various stages of the cell cycle, by activating cell signaling pathways, including tumor cell proliferation, migration and increased tumor cell pro-angiogenic factors. DNA-oxidative damage via moderate levels of ROS lead to several repercussions: it causes genomic instability, favors BCR and oncogenic kinase signaling, promotes B-cell survival and facilitates tumor progression [88]. On the contrary, high levels of ROS produce cell death. Eliminating cellular mechanisms that maintain efficient ROS levels might turn the balance of protumorigenic ROS activity toward cancer cell death. The role of antioxidant systems in carcinogenesis has been debated over the years. However, it has now been established that exaggerated antioxidant responses, regulated by specific signaling pathways, have an important impact in lymphomas. For example, various studies demonstrated that there is a correlation between rs1001179 polymorphisms and lower catalase activity which interferes with the response to oxidative stress and enhances tumorigenesis [89,90]. Catalase is an important endogenous antioxidant system that decomposes H₂O₂ into oxygen and water. In 2017, Wang et al. conducted a meta-analysis which studied the correlation between GPX-1 and cancer risk [91]. Their conclusion was that there are specific polymorphisms of this enzyme family, especially for patients with TT/CT genotype who have an increased risk of bladder cancer and brain tumors, but no evidence was found between these polymorphisms and NHL.

It is known that uric acid is the final product of purine metabolism, important components of nucleic acids and coenzymes that can be synthesized in the body or can be obtained by eating certain foods. Over the years, arguments have been brought to support the role of uric acid as an antioxidant [92,93]. This fundamental idea is supported by another study which has suggested that uric acid improves indomethacin-induced enteropathy in mice through its antioxidant effect [94]. A study conducted in 2015 assigned the link between p53 and a uric acid transporter – SLC2A9 or GLUT9 – which functions as an antioxidant, capable of protecting cells against ROS [95].

Increased ROS levels in certain tumor cells due to metabolic changes or classical chemotherapeutic use, rely on targeting specific antioxidant pathways. Thioredoxin (Trx) and GSH represent two antioxidant systems with an important role in the regulation of cellular redox homeostasis. The researchers have tried to utilize the pharmacological inhibition of antioxidant enzymes or other ROS-inducing molecules to describe the specific antioxidant defense, but with limited efficacy in monotherapy regimens. Trx family members represent a major antioxidant system, containing Trx 1 protein, thioredoxin reductase (TrxR) and NADPH. For instance, in BL cell line models two specific compounds were utilized, i.e. SK053 and adenanthin, with specific targets on Trx,

TrxR and periredoxins (Prx) 1 and 2, two H₂O₂-scavenging enzymes [96,97]. These molecules trigger ROS-induced extracellular signal-regulated kinase ½ (ERK1/2) activation and induce apoptosis. Auranofin, a gold complex, is the inhibitor of TrxR with antitumor activity in the preclinical models of chronic lymphocytic leukemia [98] and classical Hodgkin lymphoma [99]. Regarding GSH, elevated levels are associated with different types of cancer and chemoresistance [100]. Therefore, pharmacologists paid attention to a GSH-depleting agent, buthionine sulfoximine against cancer progression and chemoresistance, which is more effective in combinations with other therapeutic drugs [101].

The main subtypes and their specific features related to oxidative stress

Diffuse large B-cell lymphoma is the most frequent aggressive B-cell NHL [102]. Flow-cytometry identifies typically B-cell antigens like CD19, CD20, CD22, CD79a and CD45. Molecular features have a prognostic impact. C-MYC is a proto-oncogene on the chromosome 8q24, which confers the advantage of proliferation and growth of malignant cells when deregulated. Translocation (14;18) is associated with the overexpression of BCL-2, an antiapoptotic factor, which along with c-MYC, characterizes double-expresser lymphoma (DEL), with intermediate prognosis. When the deregulation of BCL-6 oncogene is added, the DLBCL turns to aggressive triple-hit lymphoma [103]. Four distinct genetic subtypes of the disease with recurring mutation have been recently identified by Schmitz and colleagues: MCD, BN2, N1 and EZB [104]. The MCD subtype is characterized by the presence of MYD88 and CD79 mutations, the N1 has NOTCH1 mutations, the BN2 by BCL-6 and NOTCH2 mutations and the EZB subtype has EZH2 and BCL2 translocations. These facts have an important clinical outcome, the BN2 and EZB subtype have good prognoses. Genetic mutations are not the only ones responsible for malignant evolution. As demonstrated, oxidative stress can initiate lymphomagenesis, but also the progression of the disease. A study that evaluated oxidative stress in DLBCL patients via the Free Oxygen Radical Testing (FORT) for FR and via the Free Oxygen Radical Defense (FORD) for the antioxidant status has concluded that patients with advanced stage DLBCL have a higher level of FORT and a decreased level of FORD which demonstrates that ROS are involved in NHL pathogenesis [72]. Tumors in patients with advanced disease and poor prognosis have deregulated the expression of certain ROS-metabolizing enzymes and extended pro-oxidant phenotype. According with these findings, Kinowaki et al. demonstrated the link between the overexpression of GPX4 in DLBCL and worse prognosis [105]. GPX4 is an intracellular antioxidant enzyme which prevents ROS-induced cell death. Therefore, an antioxidant treatment of advanced tumors

may help patients manage oxidative stress conditions. The Trx system defends both normal and malignant cells against oxidative stress [106]. However, the overexpression of Trx-1 gives cancer cells the advantage of growth, proliferation, survival and it also correlates with drug resistance, as reported in DLBCL-derived cell lines when compared to normal B cells, using Western blotting and real-time PCR [107]. But, the latest studies have shown a new possible hope by using pro-oxidant therapies to urge cancer cells toward death with promising aspects in B-cell malignancies. Therefore, Wang and colleagues have established that the down-regulation of Trx-1 sensitized lymphoma cells to chemotherapy regimens [108]. According to this idea, cells lacking Trx are more sensitive to ROS due to reduced proapoptotic activity of Forkhead box protein O1 (FOXO1) [109]. Trx reduces the bonds between FOXO1 and p300, formed as a response to oxidative stress. The depletion of Trx facilitated p300-mediated acetylation of FOXO1 and mediated cell death. These findings underline the role of Trx in the pathogenesis of DLBCL and are a solid argument for therapeutic exploitation. Recent studies have evaluated the involvement of the second group members thioredoxin-domain-containing (TXNDC) proteins 2,3 and 6 in DLBCL and demonstrate that these proteins are all expressed in testicular and systemic lymphomas with clinical importance [110]. This study included a limited number of cases (28 de novo confirmed systemic DLBCL and 21 testicular DLBCL) so, further investigations are needed. An interesting drug-resistance mechanism involving antioxidant enzymes was reported in ABC-DLBCL, with chronic activation BCR signaling. In these DLBCLs, the activity of STAT3 led to the upregulation of antioxidant enzyme SOD2 mitochondrial and mediated doxorubicin resistance. The use of STAT3 inhibitor oppressed SOD2-dependent resistance mechanisms and restored doxorubicin sensitivity in preclinical models [111].

Grade I and II follicular lymphoma is an indolent B cell lymphoproliferative disorder of transformed follicular center B cells, while grade III is an aggressive NHL. In FL, 85% of the cases have t(14;18) which results in the overexpression of the BCL-2 protein. Recent studies have developed a theory according to which this translocation can also be identified in normal cells, so it is considered that additional mutations are needed to produce neoplasia, such as the methyl transferase H3K27 EZH2 mutation, recognized in 27% of FL [112]. There is a particular subtype of FL, the pediatric form, which does not describe the BCL-2 rearrangement and which, according to the 2016 WHO classification, has a high possibility of curability [113]. The involvement of oxidative stress in this subtype has recently been demonstrated [84]. Peroja and colleagues evaluated redox-state regulating enzymes Prx I-VI and Trx in untreated FL [114]. In a cohort of 76 histologically

confirmed FLs, the expression of Prx I-VI, Trx and the oxidative stress marker, nitrotyrosine, were assessed. The immuno-histochemical results were correlated with clinical prognostic factors such as disease-specific survival, progression-free survival and overall survival. Their findings suggested that high Prx levels have a good disease-specific survival and overall survival which exhibit a protective role in FL patients.

Translocation (11;14) is present in most cases of *mantle cell lymphoma* with mutant implications in the BCL-1 gene. There are also forms in the absence of cyclin D1, but the overexpression of cyclin D2, with a better prognosis, is independent of the risk factors [115]. Zhang and colleagues correlated B-cell-specific transcription factor (BACH2), a tumor suppressor factor with hypoxic environment in MCL [116]. Their explanation lies in the fact that oxygen depletion produces an increased level of ROS and excessive heme, which are harmful to the body. Excess heme causes BACH2 degradation in B lymphocytes. Under hypoxic conditions, HIF-1 α independently produces the downregulation of BACH2. Under these aspects, the survival of cancer cells in MCL is ensured by the downregulation of BACH [117].

Mucosa-associated lymphoid tissue lymphoma is an indolent, multifocal lymphoma. Between 4-20% are gastric MALT lymphomas, strongly associated with the HP infection. There is a loop between HP infection-chronic inflammation-ROS release and lymphomagenesis initiation [118]. The malignant transformation of B lymphocytes occurs as a result of t(11;18), (1;14), (14;18) during the HP infection, via the activation of NF-kB [119]. If the tumor's proliferation is limited to the mucosa and it is closely related to the infectious agent, sometimes it is sufficient to eradicate the infection by means of antibiotic therapy in order to stop lymphomatous proliferation. Studies have shown that t(11;18) is associated with antibiotic resistance and a worse prognosis [120].

Small lymphocytic lymphoma is a neoplasm of mature clonal B lymphocytes with a typical immunophenotype expression of CD5 and CD23 surface antigen and mutated variable regions of the immunoglobulin heavy-chain (IGHV) genes in 50-70% of the cases [121]. The genomic background provides specific chromosomal abnormalities with prognostic importance, such as: 17p or 11q deletion indicate poor prognosis, whereas 13q deletion represents a better prognosis [122]. The role of oxidative stress in the pathogenesis of this malignancy has been discussed in several studies that have shown correlations between the level of oxidative stress markers and cytogenetic changes [123,124]. Supporting this idea, some researchers discovered that high levels of MDA, protein carbonyl and decreased levels of antioxidants (SOD and catalase) were associated with 17p deletion and worse clinical presentation [125].

Oxidative stress and NHL management

The most important findings were pointed out on the involvement of oxidative stress in the initiation and progression of NHL, but it seems that it also intervenes in the mechanisms of action of some cytostatic agents. Chemotherapeutic regimens included drugs that destroy cancer cells through different mechanisms. One possible mechanism is related to the redox cellular status. The adjustment of oxidative stress is a relevant factor in both tumor development and the responses to anticancer therapies. As seen before, ROS can stimulate tumor formation by inducing DNA mutations and pro-oncogenic signaling pathways. On the other hand, high ROS levels are usually harmful to cells and may represent a barrier for tumorigenesis. A large number of chemotherapeutic drugs exert their activity through high levels of ROS by interfering with antioxidant systems or ROS inducing pathways [126]. Cyclophosphamide is an alkylating agent used in the treatment of various cancers [127] which generates cell death through its 2 metabolites, acrolein and phosphoramidate [128]. Acrolein is responsible for the decreased overall antioxidant capacity and the activation of the stress-signaling MAP-kinases JNK, p42/44 and p38 pathways with an increased production of ROS and subsequently oxidative stress causing DNA damage, lipid peroxidation, increased permeability of the mitochondrial membrane, release of cytochrome C, activation of caspase-3 and apoptotic cell death [129]. Studies have shown that doxorubicin causes cell death by increasing ROS levels via p53-dependent manner, but it also promotes the accumulation of a transcription factor, FOXO3, which activates two apoptotic genes (Noxa and BIM) with subsequent release of cytochrome C and ROS [130]. The anti-CD20 antibody, rituximab, has a proapoptotic effect by downregulating BCL-2 (an antiapoptotic factor) and inhibiting survival p38 MAPK signal pathways. Its cytotoxic effect is also due to a complement-dependent process that generates increased amounts of ROS [131]. Glucocorticoids have a considerable effect on oxidative stress which depends on the duration of the treatment. These hormones increase the metabolic rate, mitochondrial membrane potential and mitochondrial oxidation, which in turn increases the production of superoxide, H₂O₂ and hydroxyl radicals leading to a state of cellular oxidative stress which causes oxidative damage to the DNA, protein carbonyl formation and membrane lipid peroxidation [132]. The benefits of radiotherapy (RT) for lymphomas have been well documented for many years. The RT concept is based on the alteration of DNA cancer cells, which can be done directly and indirectly [133]. The appearance of ROS is incriminated for indirect DNA damage, both in cancer cells exposed to the area of irradiation and in healthy cells at a distance from it. The

penetration of heavy particles of ionizing radiation in the body produces the breakdown of chemical bonds and, on the other hand, the water which represents half of the body weight, is split by ionizing radiation, these mechanisms favoring the assimilation of hydroxyl ROS. However, there is a thin line between the useful level and the harmful level of oxidative stress in cancer treatments. When pro-oxidant treatment is used, malignant cells generate DNA oxidation, proteins oxidation and lipid peroxidation being the cause of the increased tumor burden. Some of the antioxidants, such as vitamin C, can act both as antioxidants and pro-oxidants [134]. The pro-oxidant effect of vitamin C was observed at high doses, having an anticancer role. Ascorbate produces large amounts of H₂O₂ which activates proapoptotic signaling pathways, causes DNA damage and ultimately, cell death. Further evidence has been provided that targeting the antioxidant capacity of tumor cells can have a reliable therapeutic impact [135,136].

Nowadays, antioxidants are in the spotlight as an emerging solution to various disorders, such as cardio-metabolic disorders, solid and blood cancers via reducing the oxidative stress and the inflammation levels, e.g., increasing TAC and SOD and decreasing MDA, TNF- α and C-reactive protein concentrations, and pathogenic links between the antioxidant levels in the serum and the development of malignancies has been demonstrated [137-141]. To this regard, recent studies have focused on the effect of melatonin (MLT) in different diseases [142]. MLT is a natural hormone of the pineal gland. MLT activates MT1 and MT2 receptors and takes part in learning, memory and neuroprotection [143]. Besides its role in maintaining our wake-sleep cycle, melatonin may have anticancer activity through antiproliferative, antioxidant and immunostimulant effects via different pathways [144,145].

Yan et al. demonstrated anti-tumor activity in Hodgkin's lymphoma by inhibiting cell proliferation and by promoting apoptosis via the increased expression of LC3-II and the decreased p62 proteins [146]. Knowing its anti-inflammatory and anti-oxidant effects, it was concluded that this molecule may represent an adjuvant treatment in several types of cancer. The beneficial effect has been reflected both in the quality of life and control over the disease (growth, size, effectiveness of chemotherapies) [147,148]. The data coming from our research group which evaluated the involvement of oxidative stress in lymphoproliferative, e.g., chronic lymphocytic leukemia and DLBCL, and myeloproliferative neoplasms, e.g., essential thrombocythemia, pointed out that the aforementioned malignancies are associated with increased reactive oxygen species levels and reduced antioxidant capacity [149-152].

Highlights

- ✓ Lymphomagenesis is associated with increased oxidative stress levels.
- ✓ Oxidative stress can also be involved in the action of several chemotherapeutic drugs.
- ✓ The involvement of oxidative stress has been studied in DLBCL, FL, MCL, MALT and small lymphocytic lymphomas.

Conclusions

The current evidence suggests that oxidative stress is involved in lymphomagenesis, genetic instability, disease progression and NHL management. Further studies are therefore necessary to evaluate if and how oxidative stress-modulating therapies can influence these processes.

Conflict of interest disclosure

There are no known conflicts of interest in the publication of this article. The manuscript was read and approved by all authors.

Compliance with ethical standards

Any aspect of the work covered in this manuscript has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

References

1. Chihara DR, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implicatios for therapy. *Expert Rev Anticancer Ther.* 2015; 15(5):531-544. doi: 10.1586/14737140.2015.1023712
2. American Cancer Society. Cancer facts and figures [online]; 2019 [Accessed 29.05.2019]. Available from: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf>
3. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. *Cancer.* 1982;49(10):2112-35. doi: 10.1002/1097-0142(19820515)49:10<2112::aid-cnrcr2820491024>3.0.co;2-2
4. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood.* 1994 Sep 1;84(5):1361-92.
5. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood.* 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569
6. Ansell SM. Non-Hodgkin lymphoma: diagnosis and treatment. *Mayo Clin Proc.* 2015; 90(8):1152-1163. doi: 10.1016/j.mayocp.2015.04.025
7. Connors JM. Non-Hodgkin lymphoma: the clinician's perspective--a view from the receiving end. *Mod Pathol.* 2013 Jan;26 Suppl 1:S111-8. doi: 10.1038/modpathol.2012.184
8. Schmitz N, Zevalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. *J Clin Oncol.* 2016 Sep 10;34(26):3150-6. doi: 10.1200/JCO.2015.65.6520
9. Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. *Am J Hematol.* 2020 Mar;95(3):316-327. doi: 10.1002/ajh.25696
10. Antoine-Poirel H, Heimann P. Cytogenetic and molecular testing in lymphoma patients. *Belg J Hematol.* 2018;9(7):266-278.
11. Velavan TP. Epstein-Barr virus, malaria and endemic Burkitt lymphoma. *EBioMedicine.* 2019 Jan;39:13-14. doi: 10.1016/j.ebiom.2018.12.041
12. Yamagishi M, Fujikawa D, Watanabe T, Uchimaru K. HTLV-1-Mediated Epigenetic Pathway to Adult T-Cell Leukemia-Lymphoma. *Front Microbiol.* 2018 Jul 24;9:1686. doi: 10.3389/fmicb.2018.01686
13. Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. *Nat Rev Dis Primers.* 2019 Jan 31;5(1):9. doi: 10.1038/s41572-019-0060-9
14. Taborelli M, Polesel J, Montella M, Libra M, Tedeschi R, Battiston M, Spina M, Di Raimondo F, Pinto A, Crispo A, Grimaldi M, Franceschi S, Dal Maso L, Serraino D. Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy. *Infect Agent Cancer.* 2016 Jun 23;11:27. doi: 10.1186/s13027-016-0073-x
15. Salar A. Gastric MALT lymphoma and Helicobacter Pylori. *Medicina Clinica (Barcelona).* 2019; 152(2): 65-71. doi: 10.1016/j.medcli.2018.09.006
16. Koller MC, Aigelsreiter A. Chlamydia psittaci in ocular adnexal MALT lymphoma: a possible causative agent in the pathogenesis of this disease. *Current Clinical Microbiology Reports.* 2018; 5:261-267. doi: 10.1186/1750-9378-7-8
17. Remy R, Sylvain C, Bachy E, Bardel E. Chronic Borrelia Burgdorferi infection triggers NKT

- lymphomagenesis. *Blood*. 2018;132(25):2691-2695. doi: 10.1182/blood-2018-07-863381
18. Melenotte C, Mezouar S, Mege JL, Gorvel JP, Kroemer G, Raoult D. Bacterial infection and non-Hodgkin's lymphoma. *Crit Rev Microbiol*. 2020;46(3):270-287. doi: 10.1080/1040841X.2020.1760786
19. Re A, Cattaneo C, Rossi G. Hiv and Lymphoma: from Epidemiology to Clinical Management. *Mediterr J Hematol Infect Dis*. 2019 Jan 1;11(1):e2019004. doi: 10.4084/MJHID.2019.004
20. Travaglino A, Pace M, Varricchio S, Insabato L, Giordano C, Picardi M, Pane F, Staibano S, Mascolo M. Hashimoto Thyroiditis in Primary Thyroid Non-Hodgkin Lymphoma. *Am J Clin Pathol*. 2020 Jan 2; 153(2):156-164. doi: 10.1093/ajcp/aqz145
21. Dopart PJ, Locke SJ, Cocco P, Bassig BA, Josse PR, Stewart PA, Purdue MP, Lan Q, Rothman N, Friesen MC. Estimation of Source-Specific Occupational Benzene Exposure in a Population-Based Case-Control Study of Non-Hodgkin Lymphoma. *Ann Work Expo Health*. 2019 Oct 11;63(8):842-855. doi: 10.1093/annweh/wxz063
22. Qin L, Deng HY, Chen SJ, Wei W. A Meta-Analysis on the Relationship Between Hair Dye and the Incidence of Non-Hodgkin's Lymphoma. *Med Princ Pract*. 2019;28(3):222-230. doi: 10.1159/000496447
23. Zhang L, Rana I, Shaffer RM, Taioli E, Sheppard L. Exposure to glyphosate-based herbicides and risk for non-Hodgkin lymphoma: A meta-analysis and supporting evidence. *Mutat Res Rev Mutat Res*. 2019; 781:186-206. doi: 10.1016/j.mrrev.2019.02.001
24. Hu L, Luo D, Zhou T, Tao Y, Feng J, Mei S. The association between non-Hodgkin lymphoma and organophosphate pesticides exposure: A meta-analysis. *Environ Pollut*. 2017 Dec;231(Pt 1):319-328. doi: 10.1016/j.envpol.2017.08.028
25. Rhoades MG, Meza JL, Beseler CL, Shea PJ, Kahle A, Vose JM, Eskridge KM, Spalding RF. Atrazine and nitrate in public drinking water supplies and non-hodgkin lymphoma in nebraska, USA. *Environ Health Insights*. 2013;7:15-27. doi: 10.4137/EHL.S10629
26. Ma ES. Recurrent Cytogenetic Abnormalities in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. *Methods Mol Biol*. 2017;1541:279-293. doi: 10.1007/978-1-4939-6703-2_22
27. Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. *Blood*. 2018 May 24;131(21):2307-2319. doi: 10.1182/blood-2017-11-764332
28. López C, Kleinheinz K, Aukema SM, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. *Nat Commun*. 2019 Mar 29;10(1):1459. doi: 10.1038/s41467-019-08578-3
29. Kourentzi K, Crum M, Patil U, Prebisch A, Chavan D, Vu B, Zeng Z, Litvinov D, Zu Y, Willson RC. Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein. *Sci Rep*. 2020 Mar 19;10(1):5078. doi: 10.1038/s41598-020-61936-w
30. Jain AG, Chang CC, Ahmad S, Mori S. Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment. *Curr Treat Options Oncol*. 2019 Nov 27;20(12):85. doi: 10.1007/s11864-019-0684-8
31. Candi E, Agostini M, Melino G, Bernassola F. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. *Hum Mutat*. 2014;35(6):702-714. doi: 10.1002/humu.22523
32. Voropaeva EN, Pospelova TI, Voevoda MI, Maksimov VN, Orlov YL, Seregina OB. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma. *BMC Med Genomics*. 2019 Mar 13;12(Suppl 2):35. doi: 10.1186/s12920-019-0484-9
33. Chen PT, Jorsan K, Avezbakiyev B, Akhtar C, Wang JC. Aggressive Diffuse Intermediate Size B-Cell Lymphoma With P53 Mutation Presented as Primary Bone Marrow Lymphoma. *J Investig Med High Impact Case Rep*. 2020 Jan-Dec;8:2324709620982765. doi: 10.1177/2324709620982765
34. Brachet-Botineau M, Polomski M, Heidi AN, Juen L, Hédou D, Viaud-Massuard MC, Prié G, Gouilleux F. Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. *Cancer*. 2020;12(1):240. doi: 10.3390/cancers12010240
35. Kүçük C, Jiang B, Hu X, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from $\gamma\delta$ -T or NK cells. *Nat Commun*. 2015 Jan 14;6:6025. doi: 10.1038/ncomms7025
36. Waldmann TA, Chen J. Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. *Annu Rev Immunol*. 2017 Apr 26;35:533-550. doi: 10.1146/annurev-immunol-110416-120628
37. Gomes de Castro MA, Wildhagen H, Sograte-Idrissi S, Hitzing C, Binder M, Trepel M, Engels N, Opazo F. Differential organization of tonic and chronic B cell antigen receptors in the plasma membrane. *Nat Commun*. 2019 Feb 18;10(1):820. doi: 10.1038/s41467-019-08677-1
38. Lee J, Sengupta P, Brzostowski J, Lippincott-Schwartz J, Pierce SK. The nanoscale spatial organization of B-cell receptors on immunoglobulin M- and G-expressing human B-cells. *Mol Biol Cell*. 2017 Feb 15;28(4):511-523. doi: 10.1091/mbc.E16-06-0452
39. Efremov DG, Turkalj S, Laurenti L. Mechanisms of B cell receptor activation and responses to B cell receptor inhibitors in B cell malignancies. *Cancers*. 2020; 12(6):1396. doi: 10.3390/cancers12061396

40. Derudder E, Herzog S, Labi V, Yasuda T, Köchert K, Janz M, Villunger A, Schmidt-Supprian M, Rajewsky K. Canonical NF- κ B signaling is uniquely required for the long-term persistence of functional mature B cells. *Proc Natl Acad Sci U S A*. 2016 May 3;113(18):5065-70. doi: 10.1073/pnas.1604529113
41. Lenz G. Novel NF- κ B regulator in ABC DLBCL. *Blood*. 2016 Jun 9;127(23):2785-6. doi: 10.1182/blood-2016-03-704254
42. Jattani RP, Tritapoe JM, Pomerantz JL. Intramolecular Interactions and Regulation of Cofactor Binding by the Four Repressive Elements in the Caspase Recruitment Domain-containing Protein 11 (CARD11) Inhibitory Domain. *J Biol Chem*. 2016 Apr 15;291(16):8338-48. doi: 10.1074/jbc.M116.717322
43. Wang Z, Hutcherson SM, Yang C, Jattani RP, Tritapoe JM, Yang YK, Pomerantz JL. Coordinated regulation of scaffold opening and enzymatic activity during CARD11 signaling. *J Biol Chem*. 2019;294(40):14648-14660. doi: 10.1074/jbc.RA119.009551
44. Janovská P, Bryja V. Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas. *Br J Pharmacol*. 2017 Dec;174(24):4701-4715. doi: 10.1111/bph.13949
45. Frenquelli M, Tonon G. WNT Signaling in Hematological Malignancies. *Front Oncol*. 2020 Dec 21;10:615190. doi: 10.3389/fonc.2020.615190
46. Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. *J Hematol Oncol*. 2015 Jun 6;8:63. doi: 10.1186/s13045-015-0161-1
47. Undi RB, Gutti U, Sahu I, Sarvothaman S, Pasupuleti SR, Kandi R, Gutti RK. Wnt Signaling: Role in Regulation of Haematopoiesis. *Indian J Hematol Blood Transfus*. 2016;32(2):123-34. doi: 10.1007/s12288-015-0585-3
48. Soares-Lima SC, Pombo-de-Oliveira MS, Carneiro FRG. The multiple ways Wnt signaling contributes to acute leukemia pathogenesis. *J Leukoc Biol*. 2020 Oct;108(4):1081-1099. doi: 10.1002/JLB.2MR0420-707R
49. Yan K, Tian J, Shi W, Xia H, Zhu Y. LncRNA SNHG6 is Associated with Poor Prognosis of Gastric Cancer and Promotes Cell Proliferation and EMT through Epigenetically Silencing p27 and Sponging miR-101-3p. *Cell Physiol Biochem*. 2017;42(3):999-1012. doi: 10.1159/000478682
50. Wu X, Zhou J, Wu Z, Chen C, Liu J, Wu G, Zhai J, Liu F, Li G. miR-101-3p Suppresses HOX Transcript Antisense RNA (HOTAIR)-Induced Proliferation and Invasion Through Directly Targeting SRF in Gastric Carcinoma Cells. *Oncol Res*. 2017 Sep 21;25(8):1383-1390. doi: 10.3727/096504017X14879366402279
51. Motofei IG. Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation. *Semin Cancer Biol*. 2021 Oct 23:S1044-579X(21)00253-4. doi: 10.1016/j.semcancer.2021.10.003
52. Bao RF, Shu YJ, Hu YP, Wang XA, Zhang F, Liang HB, Ye YY, Li HF, Xiang SS, Weng H, Cao Y, Wu XS, Li ML, Wu WG, Zhang YJ, Jiang L, Dong Q, Liu YB. miR-101 targeting ZFX suppresses tumor proliferation and metastasis by regulating the MAPK/Erk and Smad pathways in gallbladder carcinoma. *Oncotarget*. 2016 Apr 19;7(16):22339-54. doi: 10.18632/oncotarget.7970
53. Huang Y, Zou Y, Lin L, Ma X, Zheng R. miR-101 regulates cell proliferation and apoptosis by targeting KDM1A in diffuse large B cell lymphoma. *Cancer Manag Res*. 2019 Apr 5;11:2739-2746. doi: 10.2147/CMAR.S197744
54. Parascandolo A, Laukkanen MO. Carcinogenesis and Reactive Oxygen Species Signaling: Interaction of the NADPH Oxidase NOX1-5 and Superoxide Dismutase 1-3 Signal Transduction Pathways. *Antioxid Redox Signal*. 2019 Jan 20;30(3):443-486. doi: 10.1089/ars.2017.7268
55. Lang JY, Ma K, Guo JX, Sun H. Oxidative stress induces B lymphocyte DNA damage and apoptosis by upregulating p66shc. *Eur Rev Med Pharmacol Sci*. 2018; 22(4):1051-1060. doi: 10.26355/eurrev_201802_14388
56. Zhou F, Shen Q, Claret FX. Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. *J Leukoc Biol*. 2013 Sep;94(3):423-9. doi: 10.1189/jlb.0113006
57. Wang L, Howell MEA, Sparks-Wallace A, Hawkins C, Nicksic CA, Kohne C, Hall KH, Moorman JP, Yao ZQ, Ning S. p62-mediated Selective autophagy endows virus-transformed cells with insusceptibility to DNA damage under oxidative stress. *PLoS Pathog*. 2019 Apr 24;15(4):e1007541. doi: 10.1371/journal.ppat.1007541
58. Moniczewski A, Gawlik M, Smaga I, Niedzielska E, Krzek J, Przegaliński E, Pera J, Filip M. Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part I. Chemical aspects and biological sources of oxidative stress in the brain. *Pharmacol Rep*. 2015 Jun;67(3):560-8. doi: 10.1016/j.pharep.2014.12.014
59. Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, Gargiulo G, Testa G, Cacciatore F, Bonaduce D, Abete P. Oxidative stress, aging, and diseases. *Clin Interv Aging*. 2018 Apr 26;13:757-772. doi: 10.2147/CIA.S158513
60. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. *Sci Transl Med*. 2014 Feb 5;6(222):222ra18. doi: 10.1126/scitranslmed.3007154

61. Wu X, Cheng J, Wang X. Dietary Antioxidants: Potential Anticancer Agents. *Nutr Cancer*. 2017;69(4): 521-533. doi: 10.1080/01635581.2017.1299872
62. Breitenbach M, Eckl P. Introduction to Oxidative Stress in Biomedical and Biological Research. *Biomolecules*. 2015;5(2):1169-77. doi: 10.3390/biom5021169
63. Simoncini C, Orsucci D, Caldarazzo Ienco E, Siciliano G, Bonuccelli U, Mancuso M. Alzheimer's pathogenesis and its link to the mitochondrion. *Oxid Med Cell Longev*. 2015;2015:803942. doi: 10.1155/2015/803942
64. Smaga I, Niedzińska E, Gawlik M, Moniczewski A, Krzek J, Przegaliński E, Pera J, Filip M. Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism. *Pharmacol Rep*. 2015;67(3):569-80. doi: 10.1016/j.pharep.2014.12.015
65. Georgescu TA, Bohiltea R, Munteanu O, Grigoriu C, Paunica I, Sajin M. A mini-review regarding the carcinogenesis and morphology of serous tumors of the ovary, fallopian tube and peritoneum. *J Mind Med Sci*. 2021;8(1):44-52. doi: 10.22543/7674.81.P4452
66. Tucker PS, Scanlan AT, Dalbo VJ. Chronic kidney disease influences multiple systems: describing the relationship between oxidative stress, inflammation, kidney damage, and concomitant disease. *Oxid Med Cell Longev*. 2015;2015:806358. doi: 10.1155/2015/806358
67. Kleinstern G, Maurer MJ, Liebow M, Habermann TM, Koff JL, Allmer C, Witzig TE, Nowakowski GS, Micallef IN, Johnston PB, Inwards DJ, Thompson CA, Feldman AL, Link BK, Flowers C, Slager SL, Cerhan JR. History of autoimmune conditions and lymphoma prognosis. *Blood Cancer J*. 2018 Aug 1;8(8):73. doi: 10.1038/s41408-018-0105-4
68. Yang S, Li JY, Xu W. Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma. *Crit Rev Oncol Hematol*. 2014;91(2):113-22. doi: 10.1016/j.critrevonc.2014.02.004
69. Liu K, Liu X, Wang M, Wang X, Kang H, Lin S, Yang P, Dai C, Xu P, Li S, Dai Z. Two common functional catalase gene polymorphisms (rs1001179 and rs794316) and cancer susceptibility: evidence from 14,942 cancer cases and 43,285 controls. *Oncotarget*. 2016 Sep 27;7(39):62954-62965. doi: 10.18632/oncotarget.10617
70. Makgoeng SB, Bolanos RS, Jeon CY, Weiss RE, Arah OA, Breen EC, Martínez-Maza O, Hussain SK. Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies. *JNCI Cancer Spectr*. 2018 Dec;2(4):pky082. doi: 10.1093/jncics/pky082
71. Gerondakis S, Siebenlist U. Roles of the NF-kappaB pathway in lymphocyte development and function. *Cold Spring Harb Perspect Biol*. 2010 May;2(5):a000182. doi: 10.1101/cshperspect.a000182
72. Gaman MA, Epingeac ME, Gaman AM. Evaluation of oxidative stress and high-density lipoprotein cholesterol levels in diffuse large B-cell lymphoma. *Rev Chim*. 2019;70(3):977-980. doi: 10.37358/RC.19.3.7043
73. Wang SS, Davis S, Cerhan JR, Hartge P, Severson RK, Cozen W, Lan Q, Welch R, Chanock SJ, Rothman N. Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. *Carcinogenesis*. 2006 Sep; 27(9):1828-34. doi: 10.1093/carcin/bgl013
74. Kim HN, Kim NY, Yu L, Kim YK, Lee IK, Yang DH, Lee JJ, Shin MH, Park KS, Choi JS, Kim HJ. Polymorphisms in DNA repair genes and MDR1 and the risk for non-Hodgkin lymphoma. *Int J Mol Sci*. 2014;15(4):6703-16. doi: 10.3390/ijms15046703
75. Thanan R, Oikawa S, Hiraku Y, Ohnishi S, Ma N, Pinlaor S, Yongvanit P, Kawanishi S, Murata M. Oxidative stress and its significant roles in neurodegenerative diseases and cancer. *Int J Mol Sci*. 2014;16(1):193-217. doi: 10.3390/ijms16010193
76. Kawanishi S, Ohnishi S, Ma N, Hiraku Y, Murata M. Crosstalk between DNA Damage and Inflammation in the Multiple Steps of Carcinogenesis. *Int J Mol Sci*. 2017 Aug 19;18(8):1808. doi: 10.3390/ijms18081808
77. Benzer F, Kandemir FM, Ozkaraca M, Kucukler S, Caglayan C. Curcumin ameliorates doxorubicin-induced cardiotoxicity by abrogation of inflammation, apoptosis, oxidative DNA damage, and protein oxidation in rats. *J Biochem Mol Toxicol*. 2018 Feb; 32(2). doi: 10.1002/jbt.22030
78. Mumcu UY, Kocer I, Ates O, Alp HH. Decreased paraoxonase1 activity and increased malondialdehyde and oxidative DNA damage levels in primary open angle glaucoma. *Int J Ophthalmol*. 2016 Oct 18; 9(10):1518-1520. doi: 10.18240/ijo.2016.10.24
79. Black CN, Bot M, Révész D, Scheffer PG, Penninx B. The association between three major physiological stress systems and oxidative DNA and lipid damage. *Psychoneuroendocrinology*. 2017 Jun;80:56-66. doi: 10.1016/j.psyneuen.2017.03.003
80. El-Mezayen HA, Darwish H, Hasheim M, El-Baz HA. Oxidant/Antioxidant Status and their Relations to Chemotherapy in Non-Hodgkin's Lymphoma. *International Journal of Pharmaceutical and Clinical Research*. 2015;7(4):269-274.
81. Jakovcevic D, Dedic-Plavetic N, Vrbanc D, Jakovcevic A, Jakic-Razumovic J. Breast Cancer Molecular Subtypes and Oxidative DNA Damage. *Appl Immunohistochem Mol Morphol*. 2015;23(10): 696-703. doi: 10.1097/PAI.0000000000000135
82. Ma-On C, Sanpavat A, Whongsiri P, Suwannasin S, Hirankarn N, Tangkijvanich P, Boonla C. Oxidative stress indicated by elevated expression of Nrf2 and 8-OHdG promotes hepatocellular carcinoma progression. *Med Oncol*. 2017 Apr;34(4):57. doi: 10.1007/s12032-017-0914-5

83. He H, Zhao Y, Wang N, Zhang L, Wang C. 8-Hydroxy-2'-deoxyguanosine expression predicts outcome of esophageal cancer. *Ann Diagn Pathol*. 2014;18(6):326-8. doi: 10.1016/j.anndiagnpath.2014.08.008
84. Kale I. The predictive role of monocyte-lymphocyte ratio and platelet-lymphocyte ratio in postmenopausal osteoporosis. *J Clin Invest Surg*. 2021;6(2):141-147. doi: 10.25083/2559.5555/6.2.9
85. Fenga C, Gangemi S, Costa C. Benzene exposure is associated with epigenetic changes (Review). *Mol Med Rep*. 2016 Apr;13(4):3401-5. doi: 10.3892/mmr.2016.4955
86. Arakaki H, Osada Y, Takashi S, Ito C, Aisa Y, Nakazato T. Oxidative Stress Is Associated with Poor Prognosis in Patients with Follicular Lymphoma. *Blood*. 2016; 128(22):1787. doi: 10.1182/blood.V128.22.1787.1787
87. Fenga C, Gangemi S, Teodoro M, Rapisarda V, Golokhvast K, Docea AO, Tsatsakis AM, Costa C. 8-Hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in workers exposed to low-dose benzene. *Toxicol Rep*. 2017 May 31;4:291-295. doi: 10.1016/j.toxrep.2017.05.008
88. Kantner HP, Warsch W, Delogu A, Bauer E, Esterbauer H, Casanova E, Sexl V, Stoiber D. ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells. *Neoplasia*. 2013 Nov;15(11):1292-300. doi: 10.1593/neo.131310
89. Rochette L, Guenancia C, Gudjoncik A, Hachet O, Zeller M, Cottin Y, Vergely C. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. *Trends Pharmacol Sci*. 2015 Jun;36(6):326-48. doi: 10.1016/j.tips.2015.03.005
90. Geybels MS, van den Brandt PA, van Schooten FJ, Verhage BA. Oxidative stress-related genetic variants, pro- and antioxidant intake and status, and advanced prostate cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2015 Jan;24(1):178-86. doi: 10.1158/1055-9965.EPI-14-0968
91. Wang C, Zhang R, Chen N, Yang L, Wang Y, Sun Y, Huang L, Zhu M, Ji Y, Li W. Association between glutathione peroxidase-1 (GPX1) Rs1050450 polymorphisms and cancer risk. *Int J Clin Exp Pathol*. 2017 Sep 1;10(9):9527-9540
92. Tasaki E, Sakurai H, Nitao M, Matsuura K, Iuchi Y. Uric acid, an important antioxidant contributing to survival in termites. *PLoS One*. 2017;12(6):e0179426. doi: 10.1371/journal.pone.0179426
93. Liu D, Yun Y, Yang D, Hu X, Dong X, Zhang N, Zhang L, Yin H, Duan W. What Is the Biological Function of Uric Acid? An Antioxidant for Neural Protection or a Biomarker for Cell Death. *Dis Markers*. 2019 Jan 10;2019:4081962. doi: 10.1155/2019/4081962
94. Yasutake Y, Tomita K, Higashiyama M, Furuhashi H, Shirakabe K, Takajo T, Maruta K, Sato H, Narimatsu K, Yoshikawa K, Okada Y, Kurihara C, Watanabe C, Komoto S, Nagao S, Matsuo H, Miura S, Hokari R. Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity. *J Gastroenterol Hepatol*. 2017 Nov;32(11):1839-1845. doi: 10.1111/jgh.13785
95. Itahana Y, Han R, Barbier S, Lei Z, Rozen S, Itahana K. The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. *Oncogene*. 2015 Apr 2;34(14):1799-810. doi: 10.1038/onc.2014.119
96. Trzeciecka A, Klossowski S, Bajor M, Zagozdzon R, Gaj P, Muchowicz A, Malinowska A, Czerwoniec A, Barankiewicz J, Domagala A, Chlebowska J, Prochorec-Sobieszek M, Winiarska M, Ostaszewski R, Gwizdalska I, Golab J, Nowis D, Firczuk M. Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma. *Oncotarget*. 2016 Jan 12;7(2):1717-31. doi: 10.18632/oncotarget.6435
97. Muchowicz A, Firczuk M, Chlebowska J, Nowis D, Stachura J, Barankiewicz J, Trzeciecka A, Klossowski S, Ostaszewski R, Zagozdzon R, Pu JX, Sun HD, Golab J. Adenanthin targets proteins involved in the regulation of disulphide bonds. *Biochem Pharmacol*. 2014;89(2):210-6. doi: 10.1016/j.bcp.2014.02.022
98. Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, Chauhan L, Rao R, Gunewardena S, Schorno K, Austin CP, Maddocks K, Byrd J, Melnick A, Huang P, Wiestner A, Bhalla KN. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. *Cancer Res*. 2014 May 1;74(9):2520-32. doi: 10.1158/0008-5472.CAN-13-2033
99. Celegato M, Borghese C, Casagrande N, Mongiat M, Kahle XU, Paulitti A, Spina M, Colombatti A, Aldinucci D. Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma. *Blood*. 2015 Sep 10;126(11):1394-7. doi: 10.1182/blood-2015-07-660365
100. Bansal A, Simon MC. Glutathione metabolism in cancer progression and treatment resistance. *J Cell Biol*. 2018 Jul 2;217(7):2291-2298. doi: 10.1083/jcb.201804161
101. Kiebal M, Skalska J, Casulo C, Brookes PS, Peterson DR, Hilchey SP, Dai Y, Grant S, Maggirwar SB, Bernstein SH. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. *Exp Hematol*. 2015;43(2):89-99. doi: 10.1016/j.exphem.2014.10.004
102. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551
103. Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi

- D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. *Blood*. 2018 May 3;131(18):2060-2064. doi: 10.1182/blood-2017-12-820605
104. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445
105. Kinowaki Y, Kurata M, Ishibashi S, Ikeda M, Tatsuzawa A, Yamamoto M, Miura O, Kitagawa M, Yamamoto K. Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma. *Lab Invest*. 2018 May;98(5):609-619. doi: 10.1038/s41374-017-0008-1
106. Zhang J, Li X, Han X, Liu R, Fang J. Targeting the Thioredoxin System for Cancer Therapy. *Trends Pharmacol Sci*. 2017 Sep;38(9):794-808. doi: 10.1016/j.tips.2017.06.001
107. Jia JJ, Geng WS, Wang ZQ, Chen L, Zeng XS. The role of thioredoxin system in cancer: strategy for cancer therapy. *Cancer Chemother Pharmacol*. 2019 Sep;84(3):453-470. doi: 10.1007/s00280-019-03869-4
108. Wang S, Lu Y, Woods K, Di Trapani G, Tonissen KF. Investigating the Thioredoxin and Glutathione Systems' Response in Lymphoma Cells after Treatment with [Au(d2pype)2]CL. *Antioxidants (Basel)*. 2021 Jan 13;10(1):104. doi: 10.3390/antiox10010104
109. Sewastianik T, Szydłowski M, Jabłonska E, Białopiotrowicz E, Kiliszek P, Gorniak P, Polak A, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Kaminski TS, Markowicz S, Nowak E, Grygorowicz MA, Warzocha K, Juszczynski P. FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism. *Oncogene*. 2016 Nov 17;35(46):5989-6000. doi: 10.1038/onc.2016.126
110. Chan MC, Savela J, Ollikainen RK, Teppo HR, Miinalainen I, Pirinen R, Kari EJM, Kuitinen H, Turpeenniemi-Hujanen T, Kuitinen O, Kuusisto MEL. Testis-Specific Thioredoxins TXNDC2, TXNDC3, and TXNDC6 Are Expressed in Both Testicular and Systemic DLBCL and Correlate with Clinical Disease Presentation. *Oxid Med Cell Longev*. 2021 Feb 1;2021:8026941. doi: 10.1155/2021/8026941
111. Mai Y, Yu JJ, Bartholdy B, Xu-Monette ZY, Knapp EE, Yuan F, Chen H, Ding BB, Yao Z, Das B, Zou Y, Young KH, Parekh S, Ye BH. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL. *Blood*. 2016 Dec 15;128(24):2797-2807. doi: 10.1182/blood-2016-03-705814
112. Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. *Am J Hematol*. 2018 Feb;93(2):296-305. doi: 10.1002/ajh.24937
113. Louissaint A Jr, Schafernak KT, Geyer JT, Kovach AE, Ghandi M, Gratzinger D, Roth CG, Paxton CN, Kim S, Namgyal C, Morin R, Morgan EA, Neuberger DS, South ST, Harris MH, Hasserjian RP, Hochberg EP, Garraway LA, Harris NL, Weinstock DM. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. *Blood*. 2016 Aug 25;128(8):1093-100. doi: 10.1182/blood-2015-12-682591
114. Peroja P, Haapasaari KM, Mannisto S, Miinalainen I, Koivunen P, Leppä S, Karjalainen-Lindsberg ML, Kuusisto ME, Turpeenniemi-Hujanen T, Kuitinen O, Karihtala P. Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma. *Virchows Arch*. 2016 May;468(5):623-30. doi: 10.1007/s00428-016-1920-2
115. Pieters T, T'Sas S, Vanhee S, Almeida A, Driège Y, Roels J, Van Loocke W, Daneels W, Baens M, Marchand A, Van Trimpont M, Matthijssens F, Morscio J, Lemeire K, Lintermans B, Reunes L, Chaltin P, Offner F, Van Dorpe J, Hochepeid T, Berx G, Beyaert R, Staal J, Van Vlierberghe P, Goossens S. Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice. *J Exp Med*. 2021 Oct 4;218(10):e20202280. doi: 10.1084/jem.20202280
116. Zhang H, Chen Z, Miranda RN, Medeiros LJ, McCarty N. Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia. *Blood*. 2017;130(6):763-776. doi: 10.1182/blood-2017-02-767293
117. Tafani M, Sansone L, Limana F, Arcangeli T, De Santis E, Polese M, Fini M, Russo MA. The Interplay of Reactive Oxygen Species, Hypoxia, Inflammation, and Sirtuins in Cancer Initiation and Progression. *Oxid Med Cell Longev*. 2016;2016:3907147. doi: 10.1155/2016/3907147
118. Marcelis L, Tousseyn T, Sagaert X. MALT Lymphoma as a Model of Chronic Inflammation-Induced Gastric Tumor Development. *Curr Top Microbiol Immunol*. 2019;421:77-106. doi: 10.1007/978-3-030-15138-6_4
119. Violeta Filip P, Cuciureanu D, Sorina Diaconu L, Maria Vladareanu A, Silvia Pop C. MALT lymphoma: epidemiology, clinical diagnosis and treatment. *J Med Life*. 2018 Jul-Sep;11(3):187-193. doi: 10.25122/jml-2018-0035

120. Juárez-Salcedo LM, Sokol L, Chavez JC, Dalia S. Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment. *Cancer Control*. 2018;25(1):1073274818778256. doi: 10.1177/1073274818778256
121. Delgado J, Nadeu F, Colomer D, Campo E. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. *Haematologica*. 2020;105(9):2205-2217. doi: 10.3324/haematol.2019.236000
122. Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksa AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, Ghia P, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K; ERIC, the European Research Initiative on CLL. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. *Blood*. 2019 Mar 14;133(11):1205-1216. doi: 10.1182/blood-2018-09-873083
123. Sabry SA, El-Senduny F, Abousamra N, El-Din MS. Interaction between Th9, interleukin-9 and oxidative stress in chronic lymphocytic leukemia. *Trends in Applied Sciences Research*. 2019;14(2):56-69. doi: 10.3923/tasr.2019.56.69
124. Zhevak T, Shelekhova T, Chesnokova N, Tsareva O, Chanturidze A, Litvitsky P, Andriutsa N, Samburova N, Budnik I. The relationship between oxidative stress and cytogenetic abnormalities in B-cell chronic lymphocytic leukemia. *Exp Mol Pathol*. 2020 Oct;116:104524. doi: 10.1016/j.yexmp.2020.104524
125. Sabry SA, El-Senduny FF, Abousamra NK, Salah El-Din M, Youssef MM. Oxidative stress in CLL patients leads to activation of Th9 cells: an experimental and comprehensive survey. *Immunol Med*. 2020;43(1):36-46. doi: 10.1080/25785826.2019.1700747
126. Zhang J, Lei W, Chen X, Wang S, Qian W. Oxidative stress response induced by chemotherapy in leukemia treatment. *Mol Clin Oncol*. 2018 Mar;8(3):391-399. doi: 10.3892/mco.2018.1549
127. Moignet A, Hasanali Z, Zambello R, Pavan L, Bateau B, Tournilhac O, Roussel M, Fest T, Awwad A, Baab K, Semenzato G, Houot R, Loughran TP Jr, Lamy T. Cyclophosphamide as a first-line therapy in LGL leukemia. *Leukemia*. 2014 May;28(5):1134-6. doi: 10.1038/leu.2013.359
128. Alqahtani S, Mahmoud AM. Gamma-Glutamylcysteine Ethyl Ester Protects against Cyclophosphamide-Induced Liver Injury and Hematologic Alterations via Upregulation of PPAR γ and Attenuation of Oxidative Stress, Inflammation, and Apoptosis. *Oxid Med Cell Longev*. 2016;2016:4016209. doi: 10.1155/2016/4016209
129. Mohammad MK, Avila D, Zhang J, Barve S, Arteel G, McClain C, Joshi-Barve S. Acrolein cytotoxicity in hepatocytes involves endoplasmic reticulum stress, mitochondrial dysfunction and oxidative stress. *Toxicol Appl Pharmacol*. 2012 Nov 15;265(1):73-82. doi: 10.1016/j.taap.2012.09.021
130. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy and Cardiotoxicity. *Cardiovasc Drugs Ther*. 2017 Feb;31(1):63-75. doi: 10.1007/s10557-016-6711-0
131. Teppo HR, Soini Y, Karihtala P. Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy. *Oxid Med Cell Longev*. 2017;2017:1485283. doi: 10.1155/2017/1485283
132. Spiers JG, Chen HJ, Sernia C, Lavidis NA. Activation of the hypothalamic-pituitary-adrenal stress axis induces cellular oxidative stress. *Front Neurosci*. 2015 Jan 19;8:456. doi: 10.3389/fnins.2014.00456
133. Hubenak JR, Zhang Q, Branch CD, Kronowitz SJ. Mechanisms of injury to normal tissue after radiotherapy: a review. *Plast Reconstr Surg*. 2014;133(1):49e-56e. doi: 10.1097/01.prs.0000440818.23647.0b
134. Castaldo SA, Freitas JR, Conchinha NV, Madureira PA. The Tumorigenic Roles of the Cellular REDOX Regulatory Systems. *Oxid Med Cell Longev*. 2016;2016:8413032. doi: 10.1155/2016/8413032
135. ALHaithloul HAS, Alotaibi MF, Bin-Jumah M, Elgebaly H, Mahmoud AM. Olea europaea leaf extract up-regulates Nrf2/ARE/HO-1 signaling and attenuates cyclophosphamide-induced oxidative stress, inflammation and apoptosis in rat kidney. *Biomed Pharmacother*. 2019 Mar;111:676-685. doi: 10.1016/j.biopha.2018.12.112
136. Yardim A, Kandemir FM, Ozdemir S, Kucukler S, Comakli S, Gur C, Celik H. Quercetin provides protection against the peripheral nerve damage caused by vincristine in rats by suppressing caspase 3, NF- κ B, ATF-6 pathways and activating Nrf2, Akt pathways. *Neurotoxicology*. 2020 Dec;81:137-146. doi: 10.1016/j.neuro.2020.10.001
137. Găman AM, Egbuna C, Găman MA. Natural bioactive lead compounds effective against haematological malignancies. In: Egbuna C, Kumar S, Ifemeje JC, Ezzat SM, Kaliyaperumal S, Editors. *Phytochemicals as Lead Compounds for New Drug Discovery*. Elsevier; 2020; pp. 95–115. doi: 10.1016/B978-0-12-817890-4.00006-8
138. Zhang Y, Jiang X, Li X, Găman MA, Kord-Varkaneh H, Rahmani J, Salehi-Sahlabadi A, Day AS, Xu Y. Serum Vitamin D Levels and Risk of Liver Cancer: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies. *Nutr Cancer*. 2021;73(8):1-9. doi: 10.1080/01635581.2020.1797127

139. Tofolean IT, Ganea C, Ionescu D, Filippi A, Garaiman A, Goicea A, Gaman MA, Dimancea A, Baran I. Cellular determinants involving mitochondrial dysfunction, oxidative stress and apoptosis correlate with the synergic cytotoxicity of epigallocatechin-3-gallate and menadione in human leukemia Jurkat T cells. *Pharmacol Res.* 2016 Jan;103:300-17. doi: 10.1016/j.phrs.2015.12.013
140. Motofei IG. Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity. *Expert Opin Drug Saf.* 2021 Dec 27:1-14. doi: 10.1080/14740338.2022.2020243
141. Montazeri RS, Fatahi S, Sohoulı MH, Abu-Zaid A, Santos HO, Găman MA, Shidfar F. The effect of nigella sativa on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials. *J Food Biochem.* 2021 Apr;45(4):e13625. doi: 10.1111/jfbc.13625
142. Sánchez A, Calpena AC, Clares B. Evaluating the Oxidative Stress in Inflammation: Role of Melatonin. *Int J Mol Sci.* 2015 Jul 27;16(8):16981-7004. doi: 10.3390/ijms160816981
143. Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. *Annu Rev Pharmacol Toxicol.* 2016;56:361-83. doi: 10.1146/annurev-pharmtox-010814-124742
144. Wang TH, Hsueh C, Chen CC, Li WS, Yeh CT, Lian JH, Chang JL, Chen CY. Melatonin Inhibits the Progression of Hepatocellular Carcinoma through MicroRNA Let7i-3p Mediated RAF1 Reduction. *Int J Mol Sci.* 2018;19(9):2687. doi: 10.3390/ijms19092687
145. Sánchez DI, González-Fernández B, Crespo I, San-Miguel B, Álvarez M, González-Gallego J, Tuñón MJ. Melatonin modulates dysregulated circadian clocks in mice with diethylnitrosamine-induced hepatocellular carcinoma. *J Pineal Res.* 2018 Oct;65(3):e12506. doi: 10.1111/jpi.12506
146. Yan G, Lei H, He M, Gong R, Wang Y, He X, Li G, Pang P, Li X, Yu S, Du W, Yuan Y. Melatonin triggers autophagic cell death by regulating RORC in Hodgkin lymphoma. *Biomed Pharmacother.* 2020 Mar;123:109811. doi: 10.1016/j.biopha.2020.109811
147. Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu DP, Li HB. Melatonin for the prevention and treatment of cancer. *Oncotarget.* 2017 Jun 13;8(24):39896-39921. doi: 10.18632/oncotarget.16379
148. Mehrzadi MH, Hosseinzadeh A, Juybari KB, Mehrzadi S. Melatonin and urological cancers: a new therapeutic approach. *Cancer Cell Int.* 2020 Sep 10;20:444. doi: 10.1186/s12935-020-01531-1
149. Gaman AM, Buga AM, Gaman MA, Popa-Wagner A. The role of oxidative stress and the effects of antioxidants on the incidence of infectious complications of chronic lymphocytic leukemia. *Oxid Med Cell Longev.* 2014;2014:158135. doi: 10.1155/2014/158135
150. Gaman AM, Moisa C, Diaconu CC, Gaman MA. Crosstalk between Oxidative Stress, Chronic Inflammation and Disease Progression in Essential Thrombocythemia. *Rev. Chim.* 2019;70(10):3486-3489. doi: 10.37358/RC.19.10.7581
151. Moisa C, Gaman MA, Diaconu CC, Gaman AM. Oxidative Stress Levels, JAK2V617F Mutational Status and Thrombotic Complications in Patients with Essential Thrombocythemia. *Rev. Chim.* 2019;70(8):2822-2825. doi: 10.37358/RC.19.8.7435.
152. Găman MA, Cozma MA, Dobrică EC, Crețoiu SM, Găman AM, Diaconu CC. Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review. *Life (Basel).* 2021 Jul 10;11(7):677. doi: 10.3390/life11070677